Vaccination Policy: It is a health policy that the government adopts for the process of vaccination. Vaccination policies have been developed over the approximately two centuries since the invention of vaccinations with the motive of suppress disease from, or boost a strong immunity system for, the population the government wants to protect. When EPI was established over 40 years ago, its main focus was on vaccinating infants with a limited number of traditional vaccines. Today the vaccine world has changed completely When EPI was established over 40 years ago, its focus was on vaccinating infants with a limited number of traditional vaccines. Today the vaccine world has changed dramatically.
Regulatory Affairs: Although the European Medicines Agency (EMA) and the World Health Organization (WHO) and the United States Food and Drug Administration (USFDA), already must established a Regulatory framework for the guideline for vaccines, the other region across the world are still at a nascent period in creating a Regulatory framework for vaccines at a national level in their own countries. As regulatory compliance for all vaccines requires some special sets of hands-on functional experience and Regulatory expertise knowledge, organizations may find it challenging to navigate through the global Regulatory framework for Vaccines.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia